Ophthalmology

Economic Burden in Late-Stage AMD High in Patients and Caregivers in US

November 12th 2024

Polygenic risk score was valuable in enhancing risk prediction models for primary open-angle glaucoma (POAG.

Woman with AMD test | Image credit: RFBSIP - stock.adobe.com

Intraocular Pressure in Glaucoma Predicted Through Machine-Learning Model

November 6th 2024

Glaucoma | Image credit: Africa Studio - stock.adobe.com

Survival Differences Seen Among Children With Retinoblastoma in European Countries

October 24th 2024

Retinoblastoma | Image credit: Pepermpron - stock.adobe.com

Evidence Suggests Association Between Eye Disease, Dementia

October 14th 2024

Man with dementia | Image credit: pathdoc - stock.adobe.com

October 8th 2024

Continuing Medical Education

View All

2.0 Credits / Ophthalmology/Optometry

Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care

1.5 Credits / Ophthalmology, Optometry

Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies

1.5 Credits / Ophthalmology/Optometry

Patient-Centered Treatment Plans for Management of Neovascular (Wet) AMD and Diabetic Macular Edema: Insights on Recent Efficacy, Safety, and Real-World Data to Improve Adherence and Outcomes

Integrating Multi-Cancer Early Detection Tests Into Clinical Practice: The Health Economics Perspective for Managed Care Professionals

1.5 Credits / Oncology

1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

More News

August 31st 2023

FDA Approves Higher-Dose Version of Aflibercept

Skylar Jeremias

The FDA approved a higher dosage of aflibercept (Eylea) for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy.

August 21st 2023

Polygenic Risk Score Identifies Individuals at Higher Risk of POAG

Individuals with a higher risk of primary open-angle glaucoma (POAG) could be identified using a polygenic risk score, recent study found.

August 17th 2023

Vision Testing Lowest in Adolescents Without Insurance

A recent study found that children who had private insurance had a higher probability of vision testing compared with uninsured and publicly insured children.

August 14th 2023

Leakage Index Associated With Macular Edema Severity

Patients with nonischemic branch retinal vein occlusion had their macular edema severity associated with leakage index.

August 7th 2023

FDA Approves New Treatment for Geographic Atrophy

The FDA approved the usage of Izervay (avacincaptad pegol) for the treatment of geographic atrophy secondary to age-related macular degeneration.

August 4th 2023

ASRS 2023: Intended vs Actual Treatment Intervals Between Intravitreal Anti-VEGF Injections: Effects of Treatment Days

Lynda Charters

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

August 2nd 2023

Smokeless Tobacco More Likely to Cause AMD, Study Suggests

Adults who used smokeless tobacco products were more likely to have age-related macular degeneration (AMD) compared with cigarette smokers.

July 27th 2023

Exposure to Statins Not Related to Increased Risk of OAG

A study conducted in Japan found that short-term exposure to statins was not associated with an increased risk of open-angle glaucoma (OAG) in a population with dyslipidemia.

July 24th 2023

Expansion of Laser Eye Surgery Not Associated With Shorter Travel Times for Care

Having optometrists perform laser eye surgery was not found to lead to a meaningful increase in nearby health care professionals for the population.

July 21st 2023

Low Vision Rehabilitation Recommended for Patients With ARMD

Patients with age-related macular degeneration (ARMD) with geographic atrophy should use low vision aids.

July 17th 2023

Atropine 0.01% Not Associated With Slowing Myopia Progression

A study that focused on children aged 5 to 12 years who lived in the United States found no difference between atropine 0.01% and placebo in treating myopia progression.

July 12th 2023

In Vitreoretinal Subspecialty, Men Have More Publications, Occupy Higher Academic Positions

A search of residency programs in the United States found that women made up about a quarter of all academic vitreoretinal specialists.

July 10th 2023

Novel Smartphone App Effective in Assessing Pediatric Ophthalmology

A smartphone app was found to be useful and reliable by clinicians when testing vision for children during the COVID-19 pandemic.

July 5th 2023

Retinopathy of Prematurity Risk Linked to Parenteral Nutrition Duration

Infants who received parenteral nutrition for at least 14 days had a higher risk of retinopathy of prematurity and receiving treatment.

June 26th 2023

Prevalence of Eye Disease Related to Diabetes Remains High in United States

A new study estimated that 9.60 million people are living with diabetic retinopathy and 1.84 million people are living with vision-threatening diabetic retinopathy in the United States.

June 19th 2023

Microbial Keratitis Severity Associated With Patient Characteristics, Location

Social risk factors, such as patient characteristics and where they live, informed the severity of microbial keratitis in a sample of patients.

June 13th 2023

Artificial Intelligence Has Potential to Estimate BCVA in Patients With DME

Fundus photographs of eyes with diabetic macular edema (DME) could be used to estimate best-corrected visual acuity (BCVA) when artificial intelligence examines the pictures.

June 9th 2023

Low-dose Atropine for Pediatric Myopia Progression Found Effective in Phase 3 Trial

Childhood myopia progression could be treated with low-dose atropine due to the safety and efficacy displayed in this study.

May 30th 2023

Infliximab, Adalimumab Have Similar Efficacy in Patients With Noninfectious Uveitis

Adalimumab had a slight advantage over infliximab in terms of adverse events when used to treat patients with noninfectious uveitis (NIU).

May 23rd 2023

Failure to Attend Follow-up Is the Main Reason for Discontinuation of Amblyopia Therapy

About 69% of pediatric patients had discontinued amblyopia therapy during COVID-19 even as their parents reported that adherence was good.

May 21st 2023

Dr Charles Wykoff: Gene Therapy for Wet AMD Would Be a Tremendous Opportunity

Gene therapies like RGX-314 are looking to treat very common diseases in ophthalmology, which would represent a tremendous opportunity for chronic disease management, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

May 16th 2023

Bevacizumab First-line Treatment More Cost-effective in RVO vs Aflibercept

Aflibercept was a less cost-effective treatment for retinal vein occlusion (RVO) compared with bevacizumab, although visual acuity outcomes were similar.

May 15th 2023

Dr Jennifer Sun Discusses the Importance of Diversity in Trials to Identify Biomarkers for Diabetic Eye Disease

There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

May 9th 2023

Myopia Associated With Increased Risk of POAG

The relationship between myopia and primary open-angle glaucoma (POAG) was stronger in Asian, Black, and Hispanic individuals compared with White individuals.

May 3rd 2023

AI Cannot Assist in Prepping for Ophthalmology Board Certification Exams, Study Finds

When presented with a set of multiple choice questions used to help trainees practice for the ophthalmology board certification exams, the artificial intelligence (AI) chatbot ChatGPT was able to answer only half correctly.

May 1st 2023

Dr Jennifer Sun Highlights Ongoing Research on Preventive Strategies for Diabetic Eye Disease

The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

April 26th 2023

Average Acuity-Based Outcomes Improved With Eyeglasses Using 0.05D Steps

Researchers found that eyeglasses with traditional steps of 0.25D were less effective and less preferred by participants compared with those refracted in 0.05D steps.

April 23rd 2023

Dr Charles Wykoff Discusses Gene Therapy to Treat Wet Age-Related Macular Degeneration

Gene therapy has the promise of being one and done, but it isn’t always that way for all patients, which leaves questions about where these therapies fit in the commercial landscape, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

April 17th 2023

ROP Incidence Increased in Premature Infants

Retinopathy of prematurity (ROP) was found to have increased from 2003 to 2019, especially in Black and Hispanic children.

April 17th 2023

Dr Darius Moshfeghi Outlines the Impact of Delayed Treatment in ROP